Allogene Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 12, 2026
ALLO$0.93-12.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
(in thousands)
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net loss | $(190,886) | $(257,590) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 37,642 | 51,743 |
| Depreciation and amortization | 12,359 | 13,639 |
| Net amortization/accretion on investment securities | (4,221) | (8,348) |
| Impairment of long-lived asset | 2,382 | 15,717 |
| Impairment of equity investment and equity method investment | — | 1,957 |
| Non-cash rent expense | 4,355 | 5,264 |
| Income tax expense | — | 443 |
| Non-cash collaboration revenue - related party | — | (14) |
| Share of loss from equity method investments | — | 1,688 |
| Changes in operating assets and liabilities: | ||
| Deposit placed in escrow | (2,706) | (20,773) |
| Prepaid expenses and other current assets | 3,238 | (492) |
| Other long-term assets | (1,290) | 4,279 |
| Accounts payable | (1,231) | (503) |
| Accrued and other current liabilities | (2,520) | (1,262) |
| Operating lease liabilities | (7,503) | (6,307) |
| Other long-term liabilities | 1,135 | 259 |
| Net cash used in operating activities | (149,246) | (200,300) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (386) | (694) |
| Proceeds from sales of investments | — | 5,398 |
| Proceeds from maturities of investments | 234,202 | 432,459 |
| Purchase of investments | (138,257) | (361,475) |
| Net cash provided by investing activities | 95,559 | 75,688 |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock from ATM offering, net of commissions and issuance costs | 22,354 | 6,764 |
| Proceeds from issuance of common stock from public offering, net of commissions and issuance costs | — | 105,283 |
| Proceeds from issuance of common stock upon exercise of stock options | — | 813 |
| Proceeds from issuance of common stock under the employee stock purchase plan | 895 | 1,535 |
| Proceeds from CIRM award | 6,908 | 2,280 |
| Net cash provided by financing activities | 30,157 | 116,675 |
| Net decrease in cash, cash equivalents and restricted cash | (23,530) | (7,937) |
| Cash, cash equivalents and restricted cash — beginning of period | 85,510 | 93,447 |
| Cash, cash equivalents and restricted cash — end of period | $61,980 | $85,510 |
| Non-cash operating, investing and financing activities: | ||
| Right-of-use asset obtained in exchange for lease liability | $— | $2,409 |
| Property and equipment purchases in accounts payable and accrued and other current liabilities | $107 | $64 |
| Supplemental disclosure: | ||
| Cash paid for amounts included in the measurement of lease liabilities | $(12,921) | $(12,505) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.